Clinical Trials Search
Clinical Trial 18930
Interventions:AMG103 (Blinatumomab); Blinatumomab; CC-5013 (Lenalidomide); Lenalidomide (Revlimid)
Study Type: Treatment
Phase of Study: Phase I
- Julio Chavez
A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement. Biological therapies, such as lenalidomide and blinatumomab, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
The primary endpoint for this study is toxicity which is coded according to the CTCAE v4. The primary objective is to determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with blinatumomab in the proposed regimen.